This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tolerability of ALK Grass Tablet in Children

This study has been completed.
Information provided by:
ALK-Abelló A/S Identifier:
First received: April 2, 2006
Last updated: May 3, 2006
Last verified: May 2006
The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years

Condition Intervention Phase
Allergy Biological: ALK Grass tablet Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of ALK Grass Tablet in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:
  • Assessment of safety by recording of adverse events

Estimated Enrollment: 32
Study Start Date: March 2006
Estimated Study Completion Date: May 2006

Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Grass pollen induced rhinoconjunctivitis
  • Boys and girls, 5-12 years of age
  • Positive skin prick test to grass pollen

Exclusion Criteria:

  • Severe asthma
  • Previous treatment with immunotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00310453

Servicio de Alergia, Hospital del Niño Jesús
Madrid, Spain, 28040
Sponsors and Collaborators
ALK-Abelló A/S
Study Director: Kim Simonsen, MD ALK-Abelló A/S, Boege Alle 6-8, 2970 Hoersholm, Denmark
  More Information Identifier: NCT00310453     History of Changes
Other Study ID Numbers: GT-09
Study First Received: April 2, 2006
Last Updated: May 3, 2006 processed this record on June 23, 2017